Science

Elvina Almuradova: ROSELLA Phase III – Adding Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

Elvina Almuradova/X

Jun 16, 2025, 09:38

Elvina Almuradova: ROSELLA Phase III – Adding Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on X:

“ROSELLA Phase III: Adding relacorilant to nab-paclitaxel in platinum-resistant ovarian cancer:

PFS: 6.5 vs 5.5 mo (HR 0.70; p=.0076)

OS (interim): 16 vs 11.5 mo (HR 0.69; p=.0121)

A promising new standard?”

Title: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Authors: Alexander B Olawaiye, Laurence Gladieff, David M O’Malley, Jae-Weon Kim, Gabriel Garbaos, Vanda Salutari, Lucy Gilbert, Linda Mileshkin, Alix Devaux, Elizabeth Hopp, Yong Jae Lee, Ana Oaknin, Mariana Scaranti, Byoung-Gie Kim, Nicoletta Colombo, Michael E McCollum, Connie Diakos, Andrew Clamp, Aliza L Leiser, Boglárka Balázs, Bradley J Monk, Giuseppa Scandurra, Emily McClung, Emilie Kaczmarek, Brian Slomovitz, Helena De La Cueva, Aknar Freire de Carvalho Calabrich, Chiara Cassani, Benoit You, Toon Van Gorp, Cristina Churruca, Giuseppe Caruso, Shibani Nicum, Andrea Bagaméri, Grazia Artioli, Lubomir Bodnar, Sokbom Kang, Ignace Vergote, Amanda Kesner-Hays, Hristina I Pashova, Sachin G Pai, Iulia Cristina Tudor, Adrian M Jubb, Domenica Lorusso

You can read the Full Article on The Lancet Journal

Elvina Almuradova: ROSELLA Phase III - Adding Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer